All In Biotech

Drug Trial Radar · NCT07308132

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies

A Phase 1, First-in-Human Study of a Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

340

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Aug 31, 2028

Study completion Oct 31, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) and for JNJ-95566692 with or without JNJ-87801493 with various standard of care (SOC) regimens (Arms C-G) in Part 1: Dose Escalation part of the study. Part 2: Dose Expansion part of the study will further characterize the safety.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

  • JNJ-95566692Drug

    JNJ-95566692 will be administered subcutaneously.

  • JNJ-87801493Drug

    JNJ-87801493 will be administered subcutaneously.

  • loncastuximab tesirineDrug

    Loncastuximab tesirine will be administered intervenously.

  • LenalidomideDrug

    Lenalidomide will be administered orally.

  • RituximabDrug

    Rituximab will be administered intravenously and may be administered subcutaneously after the first administration.

  • GemcitabineDrug

    Gemcitabine will be administered intravenously.

  • OxaliplatinDrug

    Oxaliplatin will be administered intravenously.

  • CyclophosphamideDrug

    Cyclophosphamide will be administered intravenously.

  • DoxorubicinDrug

    Doxorubicin will be administered intravenously.

  • VincristineDrug

    Vincristine will be administered intravenously.

  • PrednisoneDrug

    Prednisone will be administered orally.

  • Polatuzumab vedotinDrug

    Polatuzumab vedotin will be administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 and 2: Number of Participants with Adverse Events (AEs) And Serious Adverse Events (SAEs) by SeverityTime frame: Approximately 2 years and 8 months
  2. Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)Time frame: Approximately 2 years and 8 months

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • Monash Medical Centre

    Clayton, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Recruiting

  • Macquarie University Hospital

    North Ryde, Australia · Recruiting

  • Scientia Clinical Research

    Randwick, Australia · Recruiting

  • UZ Antwerpen

    Edegem, Belgium · Recruiting

  • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

    Liège, Belgium · Recruiting

  • Hopital Claude Huriez

    Lille, France · Recruiting

  • CHU Pitie Salpetriere

    Paris, France · Recruiting

  • CHU Lyon Sud

    Pierre-Bénite, France · Recruiting

  • Institut Universitaire du Cancer Toulouse Oncopole

    Toulouse, France · Recruiting

  • Hosp Univ Vall D Hebron

    Barcelona, Spain · Recruiting

  • Hosp. Clinic de Barcelona

    Barcelona, Spain · Recruiting

  • Hosp Univ Fund Jimenez Diaz

    Madrid, Spain · Recruiting

  • Hosp. Univ. 12 de Octubre

    Madrid, Spain · Recruiting

  • Hosp Univ Hm Sanchinarro

    Madrid, Spain · Recruiting

  • SBU Ankara Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi Faz 1 Merkezi

    Ankara, Turkey (Türkiye) · Recruiting

  • Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi

    Ankara, Turkey (Türkiye) · Recruiting

  • Memorial Antalya Hastanesi Faz 1 Klinik Arastirma Merkezi

    Antalya, Turkey (Türkiye) · Recruiting

  • Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi

    Istanbul, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.